Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Different PSA response with abiraterone acetate between mCRPC patients treated in clinical trial and clinical practice

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

YOKO Yamada

Citation

Annals of Oncology (2015) 26 (suppl_9): 71-79. 10.1093/annonc/mdv524

Authors

Y. Yamada, N. Matsubara

Author affiliations

  • Breast?oncology, National Cancer Center Hospital East, 277-0882 - Kashiwa/JP
More

Resources

Aim/Background

Previous reports have indicated that patients with cancer who are enrolled in clinical trials have better outcomes than those in clinical practice. We compared outcomes of patients treated with biraterone acetate (AA) for metastatic castration-resistant prostate cancer (CRPC) in clinical trial and in clinical practice.

Methods

We retrospectively reviewed the patient records of chemotherapy-naive patients with mCRPC treated with AA at National Cancer Center Hospital East in Japan. The primary outcome measures were to compare the rate of PSA decline ≧50% and ≧30% from baseline, and secondary outcome measures were to compare the 3-month and 6-month PSA progression-free survival (PFS).

Results

From April 2010 until April 2015, of 32 patients, 17 patients (53%) were treated with AA in a clinical trial (JPN101 and 201 trial) and 15 patients (47%) were treated in clinical practice. Patients treated in clinical trial had better performance status and heavier treatment history than patients in clinical practice. There was no significant difference in Gleason score, prior local treatment history, baseline PSA level at the time of AA initiation, the rate and the number of bone metastasis and median duration from mCRPC to AA initiation. The PSA declines ≧50% from baseline were 88% in clinical trial patients vs 47% in the clinical practice patients (p = 0.015), and ≧30% were 100% vs 60% (p = 0.006), respectively. On the other hand, 3-month and 6-month PSA PFS rates tended to be higher for patients in the clinical trials but were not statistically significant. In multivariate analysis, only treatment style (clinical trial or clinical practice) was identified as an independent predictor for PSA decline ≧ 50%.

Conclusions

Patients who were treated with AA in a clinical trial could achieve greater PSA decline than patients treated in clinical practice. However, this difference could not be adapted for PSA-PFS.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings